Until dupilumab, which belongs to a new class of biologic drugs and is sold under the brand name Dupixent, emerged a few ...

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

When conventional treatments for moderate to severe atopic dermatitis become less effective, targeted therapies may help.

Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.